Navigation Links
ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
Date:2/22/2008

roduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

ThermoGenesis Corp.

Web site: http://www.thermogenesis.com

Contact: Investor Relations

+1-916-858-5107, or

ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
2. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
3. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
4. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
5. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
6. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
7. MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 2008 UBS Healthcare Services Conference
8. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
9. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
10. Sharps Compliance Corp. Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology
11. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Regis Technologies looks forward ... for Cancer Research (AACR) annual meeting. Regis will exhibit ... starting Saturday, April 18, in Philadelphia and running through ... title of the oldest and largest organization focused on ... grants, and partners with survivors to promote awareness and ...
(Date:4/16/2015)... April 16, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... Exchange: PBT.U), is pleased to announce that the Company ... April 25, 2015 to be held in ... Bailey and Mr. James Mellon , a ... update on the key programs at its subsidiaries, Portage ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, 2015 ... and the Company), a biopharmaceutical company focused on developing ... indications, today announced that the Mayo Clinic Cancer ... site for the ongoing, multicenter Phase I/II study of ... most common and deadly form of human brain cancer. ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... Office for Eastern District of Pennsylvania and U.S. Department ... Settles State Cases with Connecticut and Massachusetts, ... today it has finalized a previously announced agreement in,principle ... of,Pennsylvania, the U.S. Department of Justice and various other ...
... exceptional individuals of all ages who,have reached beyond ... ATLANTA, Sept. 29 UCB today announced ... program, which this year awarded a,total of $300,000 ... The scholarship program was established to recognize individuals,of ...
... Bioscience GmbH,announces that it entered into a ... Icon Genetics group. It provides Nomad access ... expression,technology magnICON(R), for manufacturing biomaterials and selected,biosimilar ... provides,Nomad with a strategically needed freedom to ...
Cached Biology Technology:Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 3Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 4UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 2UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 3UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 4UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 5
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... were associated with higher levels of high sensitivity C-Reactive protein ... for heart failure patients, in research presented at the American ... high vitamin C intake from food, heart failure patients in ... times more likely to have higher levels of hsCRP, a ...
... kinase, which has been reported in other cancers such ... driver of the rapid metastasis that patients with inflammatory ... of anaplastic lymphoma kinase (ALK) inhibitors may be a ... of breast cancer. These data were presented at ...
... national panel led by Iowa State University engineers ... technologies that capture, use and sequester carbon while ... security. The 33-member National Panel for a ... time in Chicago. Participants represented universities, companies, federal ...
Cached Biology News:Low vitamin C levels may raise heart failure patients' risk 2Signaling pathway linked to inflammatory breast cancer may drive disease metastasis 2Iowa State engineers establish national panel to advance a carbon negative economy 2Iowa State engineers establish national panel to advance a carbon negative economy 3
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Inquire...
... ISOQUANT(R) Isoaspartate Detection Kit is intended for ... proteins and peptides, which can result from ... rearrangement of aspartic acid residues during storage ... depend on the monitoring of charge differences ...
...
Biology Products: